Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma

Creative Commons License

de Velasco G., Gray K. P., Hamieh L., ÜRÜN Y., Carol H. A., Fay A. P., ...Daha Fazla

EUROPEAN UROLOGY FOCUS, cilt.2, sa.6, ss.633-639, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 2 Sayı: 6
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1016/j.euf.2016.03.017
  • Dergi Adı: EUROPEAN UROLOGY FOCUS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.633-639
  • Anahtar Kelimeler: Biomarker, Genomics, Polymorphisms, Renal cell carcinoma, Single-nucleotide polymorphism, Targeted therapy
  • Ankara Üniversitesi Adresli: Evet

Özet

Background: Targeted therapy (TT) in metastatic renal cell carcinoma (mRCC) may be associated with a high rate of toxicity that undermines treatment efficacy and patient quality of life. Polymorphisms in genes involved in the pharmacokinetic pathways of TTs may predict toxicity.